Death rates from breast cancer are predicted to fall in all European Union (EU) countries in 2019 with the exception of Poland, according to new research published in the leading cancer journal Annals of Oncology today.
Mar 18, 2019
0
5
The proportion of early-stage drug trials tackling the biggest cancer killers has declined sharply since the early 1990s as less common tumour types receive increasing attention, according to new research to be presented ...
Feb 25, 2019
0
5
Men with early stage testicular cancer can safely receive one course of chemotherapy or radiotherapy after surgery without it having a long-term effect on their sperm count, according to a study published in the leading cancer ...
Feb 25, 2019
0
3
An artificial intelligence (AI) programme developed in China that combs through test results, health records and even handwritten notes diagnosed childhood diseases as accurately as doctors, researchers said Monday.
Feb 11, 2019
0
53
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial ...
Dec 13, 2018
1
14
Researchers predict that death rates from cancer will fall in 2018 in Australasian countries and in Russia. However, a greater proportion of the population will die in Russia from the disease than in any of the other countries, ...
Dec 10, 2018
0
1
Misconceptions about the use of strong opioids showed to undermine optimal pain control among Asian cancer patients undergoing chemotherapy and radiotherapy according to a cross-sectional survey conducted at the Sarawak General ...
Nov 21, 2018
0
5
Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasised, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress ...
Oct 22, 2018
0
1
Patients with human papilloma virus (HPV)-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy, according to late-breaking research reported at the ESMO 2018 Congress in Munich.
Oct 22, 2018
0
3
Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves ...
Oct 22, 2018
0
0
